Chemotherapy is definitely needed for gliomas, especially those with higher degree of malignancy, and the efficacy of chemotherapy is the most concerned issue for patients and their families. The efficacy of chemotherapy is the most concern of patients and their families. For the efficacy, it is sure that the application of targeted drugs to treat tumors has the best efficacy, so how to know what drugs are targeting at different tumors and play the maximum efficacy for different individuals? –Molecular pathology. Traditional pathology is mainly based on morphology, although with the help of many high and new technologies, such as immunohistochemistry, transmission electron microscopy, immunoelectron microscopy, morphological analysis and other means, the information provided is limited to tumors and non-tumors, benign tumors and malignant tumors, the origin of tumors, classification and grading, etc. With the development of society and medicine, the information provided is limited to the source of tumors, classification and grading. With the development of society and medicine, this information can no longer meet the needs of targeted treatment. Patients and their families want to know the prognosis of the tumor, the length of the survival period and the quality of survival, etc. As doctors, we also want to obtain information that can be based on which we can design feasible and practical treatment plans for different individuals. We have an independent molecular pathology diagnostic center for neurological tumors, which can perform fluorescence in situ hybridization (FISH) to detect heterozygous deletion, methylation and methylation of 1p/19q, and also to detect the presence of heterozygous deletion, methylation and methylation of 1p/19q. We have an independent Neurological Tumor Molecular Pathology Diagnostic Center, which can perform fluorescence in situ hybridization to detect 1p/19q heterozygous deletion, methylation-specific PCR to detect MGMT, molecular targeting of molecularly targeted drugs (EGFR gene amplification and K-ras mutation, etc.), topoisomerase II, PTEN, nuclear factor kB, CD20, etc. We will selectively carry out the molecular biology testing according to the pathological diagnosis results of different patients and the results of immunohistochemistry.